
1. Technology overview
EarlySight SA is a Swiss medtech company at Avenue de Secheron 15, 1202 Geneva. It aims to reduce vision loss through more precise detection and monitoring of eye diseases.
Its Cellularis ophthalmic camera gives cellular-level images of the retina and optic disc. Infrared transscleral flood illumination reveals the retinal pigment epithelium, and adaptive optics resolves single cells. Users can switch imaging modes, view a widefield fundus overview and store image locations for follow-up exams. AI software to analyze images and monitor disease biomarkers is stated to be in development. Specialists from several eye centers are listed as endorsers.
2. Highlighted features & specifications
- Cellular imaging: Resolves single cells of the retina and optic disc.
- Transscleral illumination: Infrared flood illumination reveals the retinal pigment epithelium.
- Adaptive optics: Corrects aberrations to reach single-cell resolution.
- Mode switching: Switch imaging modes and view a widefield fundus overview.
- Follow-up tools: Store image locations for repeat exams.
- AI analysis: Biomarker detection software stated to be under development.
3. Potential application
Research-oriented eye hospitals in Vietnam studying retinal degeneration. Clinical trial sites for retinal drugs. University ophthalmology departments.
4. Benefits
Cell-level view of the retinal pigment epithelium that standard fundus imaging does not show. Multiple imaging modes in one camera. Stored image locations support precise follow-up of the same area. Suited to clinical research on retinal disease and drug trials.
5. Market trends & opportunities
Retinal diseases need earlier, more granular biomarkers, and ophthalmic drug trials increasingly use advanced imaging endpoints. Eye clinics and research centers in Southeast Asia face rising demand from diabetic eye disease and ageing.
6. Other information
Swiss company in Geneva (EarlySight SA). Seed round extended to CHF 6.1 million in September 2025 with Zurcher Kantonalbank joining; strategic collaboration with RetinAI in December 2025; ISO 13485 certification announced March 2022; ranked in the Top 100 Swiss Startups 2024. Founding year not stated; the site does not mention CE or FDA status.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































